NASDAQ:LGVN Longeveron (LGVN) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free LGVN Stock Alerts $1.68 0.00 (0.00%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$1.65▼$1.7350-Day Range$1.67▼$5.7952-Week Range$1.60▼$44.00Volume347,788 shsAverage Volume1.53 million shsMarket Capitalization$4.22 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Longeveron alerts: Email Address Longeveron MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside614.3% Upside$12.00 Price TargetShort InterestBearish9.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.60Based on 6 Articles This WeekInsider TradingAcquiring Shares$350,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($6.77) to ($5.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.38 out of 5 stars 3.5 Analyst's Opinion Consensus RatingLongeveron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLongeveron has only been the subject of 1 research reports in the past 90 days.Read more about Longeveron's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.34% of the float of Longeveron has been sold short.Short Interest Ratio / Days to CoverLongeveron has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Longeveron has recently increased by 224.20%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLongeveron does not currently pay a dividend.Dividend GrowthLongeveron does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LGVN. Previous Next 3.7 News and Social Media Coverage News SentimentLongeveron has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Longeveron this week, compared to 1 article on an average week.Search Interest16 people have searched for LGVN on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows11 people have added Longeveron to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Longeveron insiders have bought more of their company's stock than they have sold. Specifically, they have bought $350,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders24.34% of the stock of Longeveron is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.01% of the stock of Longeveron is held by institutions.Read more about Longeveron's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Longeveron are expected to grow in the coming year, from ($6.77) to ($5.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Longeveron is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Longeveron is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLongeveron has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Longeveron's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Smallcaps DailyThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySee how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.Click to read About Longeveron Stock (NASDAQ:LGVN)Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.Read More LGVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGVN Stock News HeadlinesApril 13, 2024 | insidertrades.comMohamed Wa'el Ahmed Hashad Acquires 10,638 Shares of Longeveron Inc. (NASDAQ:LGVN) StockMay 2, 2024 | globenewswire.comLongeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024May 8, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 2, 2024 | americanbankingnews.comHC Wainwright Weighs in on Longeveron Inc.'s Q1 2024 Earnings (NASDAQ:LGVN)May 1, 2024 | finance.yahoo.comLongeveron Inc. (LGVN)April 30, 2024 | americanbankingnews.comLongeveron (NASDAQ:LGVN) Given New $12.00 Price Target at HC WainwrightApril 25, 2024 | globenewswire.comLongeveron to Present at the Planet MicroCap ShowcaseApril 20, 2024 | investing.comLongeveron secures $11.4 million from warrant exercisesMay 8, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 18, 2024 | globenewswire.comLongeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public OfferingApril 17, 2024 | globenewswire.comLongeveron Announces Exercise of Warrants for $6.2 Million Gross ProceedsApril 15, 2024 | msn.comLongeveron stock rallies 85% on Alzheimer's presentation (update)April 15, 2024 | msn.comWhat's Going On With Longeveron Stock?April 15, 2024 | markets.businessinsider.comWhy Is Longeveron (LGVN) Stock Up 48% Today?April 15, 2024 | finance.yahoo.comLongeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)April 15, 2024 | globenewswire.comLongeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)April 15, 2024 | investorplace.comWhy Is Longeveron (LGVN) Stock Up 48% Today?April 13, 2024 | finance.yahoo.comChief Scientific Officer Joshua Hare Acquires 148,936 Shares of Longeveron Inc (LGVN)April 11, 2024 | globenewswire.comLongeveron Announces Closing of $5.2 Million Public OfferingApril 8, 2024 | globenewswire.comLongeveron Announces Pricing of $5.25 Million Public OfferingApril 8, 2024 | globenewswire.comLongeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and GoalsApril 8, 2024 | investorplace.comWhy Is Longeveron (LGVN) Stock Up 82% Today?March 19, 2024 | globenewswire.comLongeveron Announces 1-for-10 Reverse Stock SplitMarch 1, 2024 | finance.yahoo.comLongeveron Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 29, 2024 | seekingalpha.comLongeveron Inc. (LGVN) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | investing.comLongeveron LLC earnings missed by $0.81, revenue topped estimatesFebruary 28, 2024 | finance.yahoo.comLongeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call TranscriptSee More Headlines Receive LGVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/07/2024Next Earnings (Confirmed)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LGVN CUSIPN/A CIK1721484 Webwww.longeveron.com Phone305-302-7158FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+614.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($10.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,410,000.00 Net Margins-3,020.17% Pretax Margin-3,020.17% Return on Equity-209.14% Return on Assets-136.82% Debt Debt-to-Equity Ratio0.21 Current Ratio1.50 Quick Ratio1.50 Sales & Book Value Annual Sales$710,000.00 Price / Sales5.94 Cash FlowN/A Price / Cash FlowN/A Book Value$2.68 per share Price / Book0.63Miscellaneous Outstanding Shares2,510,000Free Float1,901,000Market Cap$4.22 million OptionableNot Optionable Beta0.51 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Joshua Michael Hare FACC (Age 61)M.D., Co-Founder, Chief Science Officer & Chairman Comp: $74kMr. Mohamed Wa'el Ahmed Hashad (Age 62)CEO & Director Comp: $781.56kMs. Lisa A. Locklear M.B.A. (Age 62)Executive VP & CFO Comp: $248.38kMr. Paul T. Lehr J.D. (Age 56)International Executive Director, General Counsel & Secretary Comp: $554.05kDr. Dan Gincel Ph.D. (Age 53)Senior Vice President of Strategic Collaborations & Scientific Affairs Dr. Nataliya Agafanova M.D. (Age 54)Chief Medical Officer Ms. Elly Ryu (Age 42)VP & Corporate Controller More ExecutivesKey CompetitorsEnsysce BiosciencesNASDAQ:ENSCArtelo BiosciencesNASDAQ:ARTLSoligenixNASDAQ:SNGXExicureNASDAQ:XCURTharimmuneNASDAQ:THARView All CompetitorsInsiders & InstitutionsRock SofferBought 31,915 shares on 4/11/2024Total: $75,000.25 ($2.35/share)Mohamed Wa'el Ahmed HashadBought 10,638 shares on 4/11/2024Total: $24,999.30 ($2.35/share)Joshua HareBought 106,383 shares on 4/10/2024Total: $250,000.05 ($2.35/share)Armistice Capital LLCBought 1,836,000 shares on 2/13/2024Ownership: 7.312%Cathy RossBought 500 shares on 1/10/2024Total: $6,550.00 ($13.10/share)View All Insider TransactionsView All Institutional Transactions LGVN Stock Analysis - Frequently Asked Questions Should I buy or sell Longeveron stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Longeveron in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LGVN shares. View LGVN analyst ratings or view top-rated stocks. What is Longeveron's stock price target for 2024? 1 Wall Street research analysts have issued 12 month target prices for Longeveron's shares. Their LGVN share price targets range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price. View analysts price targets for LGVN or view top-rated stocks among Wall Street analysts. How have LGVN shares performed in 2024? Longeveron's stock was trading at $13.60 on January 1st, 2024. Since then, LGVN shares have decreased by 87.6% and is now trading at $1.68. View the best growth stocks for 2024 here. Are investors shorting Longeveron? Longeveron saw a increase in short interest in April. As of April 15th, there was short interest totaling 91,100 shares, an increase of 224.2% from the March 31st total of 28,100 shares. Based on an average trading volume of 2,010,000 shares, the short-interest ratio is currently 0.0 days. Currently, 9.3% of the shares of the company are sold short. View Longeveron's Short Interest. When is Longeveron's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our LGVN earnings forecast. How can I listen to Longeveron's earnings call? Longeveron will be holding an earnings conference call on Tuesday, May 14th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Longeveron's earnings last quarter? Longeveron Inc. (NASDAQ:LGVN) released its earnings results on Tuesday, February, 27th. The company reported ($2.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.10) by $0.40. The business earned $0.06 million during the quarter, compared to analysts' expectations of $0.21 million. Longeveron had a negative trailing twelve-month return on equity of 209.14% and a negative net margin of 3,020.17%. When did Longeveron's stock split? Longeveron shares reverse split before market open on Wednesday, March 27th 2024. The 1-10 reverse split was announced on Wednesday, March 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Longeveron IPO? Longeveron (LGVN) raised $30 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. acted as the underwriters for the IPO. How do I buy shares of Longeveron? Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LGVN) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorStock-Picking AI Predicts #1 Stock of 2024Altimetry[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
